profit from every $100 of sales.
$0$100
Alpha Teknova
$8.62-1.26% today
+75.9% in 1 year
1-year low $1.991-year high $9.33
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Alpha Teknova sold, what it kept, and what it did with the cash.
Sales went from $41.4 million in 2022 to $40.5 million in 2025, with -$17.3 million of profit last year.
SalesProfit
Alpha Teknova vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Alpha Teknova | No profit yet | ||
 Merck KGaA | 25.3× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Alpha Teknova's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 41 | 37 | 38 | 41 | |
| 17 | 10 | 7 | 13 | |
| -29 | -31 | -26 | -17 | |
| -26 | -31 | -20 | -10 | |
| -47 | -37 | -27 | -17 | |
| -1.69 | -1.16 | -0.57 | -0.32 | |
| 42.2% | 28.1% | 19.2% | 33.2% | |
| -69.7% | -85.0% | -69.3% | -41.9% | |
| -114.6% | -100.3% | -70.9% | -42.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 152 | 129 | 119 | 104 |
| Cash | 42 | 28 | 4 | 6 |
| Total debt | 42 | 30 | 30 | 28 |
| Total liabilities | 52 | 39 | 36 | 35 |
| 100 | 90 | 82 | 69 | |
| 28 | 32 | 47 | 53 | |
| -16.0% | -23.8% | -18.3% | -13.4% | |
| -47.5% | -40.9% | -32.5% | -25.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -27 | -19 | -12 | -9 | |
| 28 | 8 | 1 | 1 | |
| -56 | -27 | -14 | -10 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 4 | 4 | 3 |
Valuation
- –
- –
- –
- 3.2×
- 13.4×
- –
- –
- -1.8%
- -3.2%
- 0.0%
Profitability
- 33.2%
- -41.9%
- -42.6%
- -23.9%
- -17.4%
- -22.9%
- -24.3%
- -17.4%
- -17.8%
- 5.4%
Growth
- −0.7%
- –
- +27.5%
- –
- +17.5%
Financial health
- –
- 0.23
- 14.9%
- -20.8×
- 4.59
- 3.60
- 0.42
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 958
Bottom 7%of 889
Bottom 16%of 890
Bottom 29%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.08 | -0.09 | +13.6% |
| Feb 26, 2026 | -0.09 | -0.09 | +0.0% |
| Nov 6, 2025 | -0.08 | -0.09 | +14.7% |
| Aug 7, 2025 | -0.07 | -0.10 | +30.3% |
| May 8, 2025 | -0.09 | -0.11 | +18.2% |
| Mar 4, 2025 | -0.11 | -0.12 | +8.3% |
| Nov 7, 2024 | -0.15 | -0.11 | −36.4% |
| Aug 13, 2024 | -0.13 | -0.16 | +18.8% |
News
Alpha and Omega Semiconductor surges over 20% for second consecutive sessionSeeking Alpha · Nov 9, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
38No pass
Philip Fisher
21No pass
Peter Lynch
26No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
20No pass
Questions about Alpha Teknova
Is Alpha Teknova a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Alpha Teknova AI analysis
What does Alpha Teknova do?
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. It is in Drug Manufacturers - Specialty & Generic.
Does Alpha Teknova pay a dividend?
No. Alpha Teknova does not pay a dividend at the moment.
Is Alpha Teknova stock halal?
Yes. Alpha Teknova passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has Alpha Teknova stock done over the past year?
Up 75.9% over the past twelve months, to $8.62. It traded between $1.99 and $9.33 and is 7.6% below its high.
Who are Alpha Teknova's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Alpha Teknova's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.